{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-07T05:11:39.998545+00:00","company":{"ticker":"LPCN","cik":1535955,"company_name":"Lipocine Inc."},"pagination":{"limit":100,"returned":6,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"55ea8acd9fa31bc1c6648b15bc8253585e545cab","cik":1535955,"ticker":"LPCN","company_name":"Lipocine Inc.","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":"($0.52) per diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss of $3.7 million","period_text":"First Quarter Ended March 31, 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":null},"claim":"Lipocine Inc. reported First Quarter Ended March 31, 2026 results: net income net loss of $3.7 million, EPS ($0.52) per diluted share.","evidence_excerpt":"Lipocine reported a net loss of $3.7 million, or ($0.52) per diluted share, for the quarter ended March 31, 2026, compared with a net loss of $1.9 million, or ($0.35) per diluted share, for the quarter ended March 31, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-26-021638","anchor_url":"https://secwatch.observer/filing/0001493152-26-021638#claim-55ea8acd9fa31bc1c6648b15bc8253585e545cab","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1535955/000149315226021638/0001493152-26-021638-index.htm"},{"fact_type":"governance_change","fact_key":"b565707ccff3f04998b9bf7f15164b6a7cf5923b","cik":1535955,"ticker":"LPCN","company_name":"Lipocine Inc.","filed_at":"2025-06-04T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-06-04","item_codes_triggered":["5.03"],"summary_text":"Reduction of authorized common stock from 200,000,000 to 75,000,000 shares via amendment to Amended and Restated Certificate of Incorporation"},"claim":"Lipocine Inc.: Reduction of authorized common stock from 200,000,000 to 75,000,000 shares via amendment to Amended and Restated Certificate of Incorporation (effective 2025-06-04).","evidence_excerpt":"On June 4, 2025, the Company filed the Amendment with the Secretary of State of the State of Delaware.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001641172-25-013603","anchor_url":"https://secwatch.observer/filing/0001641172-25-013603#claim-b565707ccff3f04998b9bf7f15164b6a7cf5923b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1535955/000164117225013603/0001641172-25-013603-index.htm"},{"fact_type":"material_agreement","fact_key":"e0d1e950474ba07f93ae5c6658ddc8c1a32e3580","cik":1535955,"ticker":"LPCN","company_name":"Lipocine Inc.","filed_at":"2024-04-26T23:59:59+00:00","payload":{"action":"termination","agreement_name":"Controlled Equity Offering Sales Agreement","agreement_type":"atm_program","counterparty":"Cantor Fitzgerald & Co.","effective_date":"2024-04-24","item_codes_triggered":["1.02"],"value_text":"terminated effective immediately upon notice; waiver of notice period"},"claim":"Lipocine Inc. terminated Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. valued at terminated effective immediately upon notice; waiver of notice period (effective 2024-04-24).","evidence_excerpt":"On April 24, 2024, the Company provided notice to Cantor Fitzgerald & Co. (“Cantor”) of its election to terminate the Controlled Equity Offering SM Sales Agreement between them dated March 6, 2017 (the “Sales Agreement”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-016777","anchor_url":"https://secwatch.observer/filing/0001493152-24-016777#claim-e0d1e950474ba07f93ae5c6658ddc8c1a32e3580","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1535955/000149315224016777/0001493152-24-016777-index.htm"},{"fact_type":"material_agreement","fact_key":"2ed5ea9b98fb4be39602e421bd3583fecd0c9aa2","cik":1535955,"ticker":"LPCN","company_name":"Lipocine Inc.","filed_at":"2024-04-26T23:59:59+00:00","payload":{"action":"entry","agreement_name":"ATM Agreement","agreement_type":"atm_program","counterparty":"A.G.P./Alliance Global Partners","effective_date":"2024-04-26","item_codes_triggered":["1.01"],"value_text":"up to $10,616,169 of Shares; 3.0% of aggregate gross proceeds per sale"},"claim":"Lipocine Inc. entered into ATM Agreement with A.G.P./Alliance Global Partners valued at up to $10,616,169 of Shares; 3.0% of aggregate gross proceeds per sale (effective 2024-04-26).","evidence_excerpt":"On April 26, 2024, Lipocine Inc. (the “Company”), entered into a sales agreement (the “ATM Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”), as sales agent, pursuant to which the Company may offer and sell shares of common stock, par value $0.0001 per share (the “Shares”), from time to time, in an at-the-market public offering.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-016777","anchor_url":"https://secwatch.observer/filing/0001493152-24-016777#claim-2ed5ea9b98fb4be39602e421bd3583fecd0c9aa2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1535955/000149315224016777/0001493152-24-016777-index.htm"},{"fact_type":"earnings_release","fact_key":"6de3160df5d2d14ec16ca916f9b1a39e69fcdb59","cik":1535955,"ticker":"LPCN","company_name":"Lipocine Inc.","filed_at":"2024-03-07T23:59:59+00:00","payload":{"eps_text":"($3.14) per diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss of $16.4 million","period_text":"the year ended December 31, 2023","report_date":"2024-03-07","result_type":"reported_results","revenue_text":"$2.9 million"},"claim":"Lipocine Inc. reported the year ended December 31, 2023 results: revenue $2.9 million, net income net loss of $16.4 million, EPS ($3.14) per diluted share.","evidence_excerpt":"per diluted share, for the year ended December 31, 2022. During\n2023 Lipocine recognized a non-cash minimum guaranteed royalties reversal of variable consideration revenue of $2.9 million related to\nthe termination of the Antares License Agreement. The reversal of revenue is due to the fact that, as a result of the termination\nof the license agreement, the Company","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-009128","anchor_url":"https://secwatch.observer/filing/0001493152-24-009128#claim-6de3160df5d2d14ec16ca916f9b1a39e69fcdb59","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1535955/000149315224009128/0001493152-24-009128-index.htm"},{"fact_type":"material_agreement","fact_key":"d136ed62a48c994634dbb31cb735f119448940e9","cik":1535955,"ticker":"LPCN","company_name":"Lipocine Inc.","filed_at":"2024-01-18T23:59:59+00:00","payload":{"action":"entry","agreement_name":"License Agreement","agreement_type":"license","counterparty":"Gordon Silver Limited and Verity Pharmaceuticals, Inc.","effective_date":"2024-01-12","item_codes_triggered":["1.01"],"value_text":"$11 million license fee"},"claim":"Lipocine Inc. entered into License Agreement with Gordon Silver Limited and Verity Pharmaceuticals, Inc. valued at $11 million license fee (effective 2024-01-12).","evidence_excerpt":"On January 12, 2024, Lipocine Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Gordon Silver Limited (“GSL”) and Verity Pharmaceuticals, Inc. (“Verity Pharma”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-002831","anchor_url":"https://secwatch.observer/filing/0001493152-24-002831#claim-d136ed62a48c994634dbb31cb735f119448940e9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1535955/000149315224002831/0001493152-24-002831-index.htm"}]}